Background
The number of people with type II diabetes mellitus is increasing [1]. Due to the high burden of diabetes in particular and chronic diseases in general for healthcare costs and their impact on quality of life, management of these diseases has become an important issue in health policy in many countries [2]. This has triggered the design and introduction of disease management programmes (DMPs) for type II diabetes mellitus in particular